Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Operating Expenses (2016)

Lixte Biotechnology Holdings' Operating Expenses history spans 7 years, with the latest figure at $516268.0 for Q4 2016.

  • For Q4 2016, Operating Expenses changed N/A year-over-year to $516268.0; the TTM value through Dec 2016 reached $2.1 million, up 5.04%, while the annual FY2025 figure was $5.1 million, 42.96% up from the prior year.
  • Operating Expenses reached $516268.0 in Q4 2016 per LIXT's latest filing, down from $647077.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.2 million in Q4 2013 to a low of $313052.0 in Q3 2013.
  • Average Operating Expenses over 5 years is $1.7 million, with a median of $536148.5 recorded in 2014.
  • Peak YoY movement for Operating Expenses: crashed 62.65% in 2013, then skyrocketed 114.34% in 2014.
  • A 5-year view of Operating Expenses shows it stood at $9.9 million in 2012, then increased by 13.95% to $11.2 million in 2013, then crashed by 95.53% to $501420.0 in 2014, then skyrocketed by 55.5% to $779712.0 in 2015, then plummeted by 33.79% to $516268.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Operating Expenses are $516268.0 (Q4 2016), $647077.0 (Q3 2016), and $555017.0 (Q2 2016).